Milrinone improves arterial oxygenation in dogs with acute lung injury induced by oleic acid.
The aim of the study was to investigate effects of milrinone on pulmonary permeability in dogs with acute lung injury induced by oleic acid. To induce acute lung injury, we administered 0.08 mg/kg of oleic acid to 19 adult mongrel dogs and then measured hemodynamic parameters and performed blood gas analysis. An injection of oleic acid depressed the mean arterial pressure, cardiac index, and arterial oxygenation. Dogs were divided into three groups: six received a bolus of milrinone (50 microg/kg) followed by a continuous (0.5 microg/kg/min, low-dose), seven received a bolus (100 microg/kg) followed by a continuous (1.0 microg/kg/min; i.e., a low-dose twice; high-dose), and six no milrinone (control). Milrinone administration improved the cardiac index and arterial oxygenation and simultaneously depressed the intrapulmonary shunt fraction and the extravascular thermal lung water as extravascular water content of the lung. These changes produced by milrinone are different according to the doses. In conclusion, milrinone acts on the capillary endothelium and inhibits an accumulation in the extravascular water content of the lung, which may induce an improvement in arterial oxygenation. Milrinone may also improve arterial oxygenation through an inhibition of platelet aggregation and chemical mediators that are released from platelets. The latter mechanism also may improve arterial oxygenation, and the exact property responsible for causing the effect of milrinone has not yet been identified.
Tanaka
H
H
Trauma and Critical Care Center, Teikyo University School of Medicine, Tokyo, Japan.
Tajimi
K
K
Kobayashi
K
K
D000818:Animals; D002302:Cardiac Output / Q000187:drug effects; D004285:Dogs; D015633:Extravascular Lung Water / Q000187:drug effects / Q000502:physiology; D006439:Hemodynamics / Q000187:drug effects; D020105:Milrinone / Q000494:pharmacology*; D019301:Oleic Acid; D010100:Oxygen / Q000097:blood*; D010101:Oxygen Consumption / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D011652:Pulmonary Circulation / Q000187:drug effects / Q000502:physiology; D011654:Pulmonary Edema / Q000139:chemically induced* / Q000378:metabolism* / Q000503:physiopathology; D013997:Time Factors
D010726:Phosphodiesterase Inhibitors; D019301:Oleic Acid; D020105:Milrinone; D010100:Oxygen